CoChat

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms

Parampalli Yajnanarayana, Sowmya, Stübig, Thomas, Cornez, Isabelle, Alchalby, Haefaa, Schönberg, Kathrin, Rudolph, Janna, Triviai, Ioanna, Wolschke, Christine, Heine, Annkristin, Brossart, Peter, Kröger, Nicolaus, Wolf, Dominik · 2015 · British Journal of Haematology
Cited by 162

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Summary: Ruxolitinib (INCB 018424) is the first JAK 1/JAK 2 inhibitor approved for treatment of myelofibrosis. JAK/STAT‐signalling is known to be involved in the regulation of CD 4+ T cells, which critically orchestrate inflammatory responses. To better understand how ruxolitinib modulates CD 4+ T cell responses, we undertook an in‐depth analysis of CD 4+ T cell function upon ruxolitinib exposure. We observed a decrease in total CD 3+ cells after 3 weeks of ruxolitinib treatment in patients with myeloproliferative neoplasms. Moreover, we found that the number of regulatory T cells (Tregs), pro‐inflammatory T‐helper cell types 1 (Th1) and Th17 were reduced, which were validated by in vitro studies. In line with our in vitro data, we found that inflammatory cytokines [tumour necrosis factor‐α (TNF), interleukin (IL)5, IL 6, IL 1B] were also downregulated in T cells from patients (all P < 0·05). Finally, we showed that ruxolitinib does not interfere with the T cell receptor signalling pathway, but impacts IL 2‐dependent STAT 5 activation. These data provide a rationale for testing JAK inhibitors in diseases triggered by hyperactive CD 4+ T cells, such as autoimmune diseases. In addition, they also provide a potential explanation for the increased infection rates (i.e. viral reactivation and urinary tract infection) seen in ruxolitinib‐treated patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.13373

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 162

Metadata

Authors
Parampalli Yajnanarayana, S., Stübig, T., Cornez, I., Alchalby, H., Schönberg, K., Rudolph, J., Triviai, I., Wolschke, C., Heine, A., Brossart, P., Kröger, N., & Wolf, D.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2015-03-30
Volume
169
Issue
6
Pages
824-833
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2031251938
Cited by
162
References
6
FWCI
8.32
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. https://app.cochat.ai/papers/10.1111/bjh.13373
The paper
Parampalli Yajnanarayana, S., Stübig, T., Cornez, I., Alchalby, H., Schönberg, K., Rudolph, J., Triviai, I., Wolschke, C., Heine, A., Brossart, P., Kröger, N., & Wolf, D. (2015). JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. British Journal of Haematology. https://doi.org/10.1111/bjh.13373

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.